Bioventix PLC
Climate Impact & Sustainability Data (2021, 2022)
Reporting Period: 2021
Environmental Metrics
ESG Focus Areas
- Social
- Environmental
- Governance
Environmental Achievements
- Completed significant refurbishment of facilities ensuring improved water utilisation and energy efficiency.
- Encouraged staff to reduce wastage, optimize use of resources, and switch off electrical equipment when not in use.
- Reduced business travel through greater adoption of technology for virtual meetings.
Social Achievements
- Maintained regular communication and dialogue with stakeholders.
- Applied fair employment practices and complied with all employment legislation.
- Invested in healthy and safe workplaces and implemented various employee policies (Equal Opportunities, Anti-harassment, Health and Safety, GDPR, Flexible Working, Parental Leave, etc.).
- Supported staff working from home during the COVID-19 pandemic.
- Maintained open communication with staff regarding company strategy and performance.
Governance Achievements
- Adopted the QCA Corporate Governance Code.
- Undertook an annual review of the corporate governance framework.
- Established an Audit Committee, a Remuneration Committee, and a Nominations Committee.
- Implemented a comprehensive suite of policies covering conduct and ethics (anti-bribery, modern slavery, safeguarding).
Climate Goals & Targets
Medium-term Goals:
- Continued roll-out of high sensitivity troponin assays.
Short-term Goals:
- Explore production systems (such as E.coli) to improve production techniques for biotin blockers and THC/cannabis antibodies.
Environmental Challenges
- Adverse impact of foreign exchange movements.
- Increased charge in respect of share options issued in previous years.
- Flatter downstream market for vitamin D testing and pandemic effects.
- Regulatory approvals for domestic Chinese customers have considerable lead times.
- Development of antibody technology companies in China represents a longer-term challenge.
- Relative global geopolitical stability will be important for continued trade.
- COVID-19 pandemic adversely affected routine diagnostic pathways and patient willingness to seek healthcare.
- Supply chain issues caused by various factors (reagents, plastics, filters).
- Some lost opportunities for SMA technology due to competition from rabbit monoclonal and synthetic antibody technologies.
Mitigation Strategies
- Careful stock planning and sourcing alternatives to manage supply chain issues.
- Continued investment in research projects.
- Maintaining a cash balance of approximately £5 million to facilitate operational and strategic agility.
- Exploring production systems (such as E.coli) to improve production techniques and commercial feasibility.
- Working with a UK industrial site to conduct a field trial of a pyrene exposure device and app.
Supply Chain Management
Responsible Procurement
- Careful stock planning and sourcing alternatives.
Climate-Related Risks & Opportunities
Sustainable Products & Innovation
- Pyrene exposure device and app
Reporting Period: 2022
Environmental Metrics
ESG Focus Areas
- Environmental
- Social
- Governance
Environmental Achievements
- Converted one process to use bioreactors, reducing plastic flask usage.
- Implemented genetic engineering techniques resulting in a four-fold increase in the yield of one antibody production.
- Using SMAs made in vitro to replace mass immunization of sheep for T4 (thyroxine) antibody, reducing animal usage.
- Significant refurbishment of facilities improving water usage and energy efficiency.
Social Achievements
- Maintained regular communication and dialogue with stakeholders.
- Applied fair employment practices and complied with all legislation and requirements regarding employment.
- Invested in healthy and safe workplaces.
- Supported new parents in their desire to return to work, resulting in four part-time employees.
Governance Achievements
- Followed the guidelines of the Quoted Companies Alliance.
- Continued efforts to increase Board diversity.
- Operates a Quality Management System based on the principles of ISO 9001:2015 and ISO 13485:2016.
Climate Goals & Targets
Long-term Goals:
- Extend success to dementia diagnostics.
Short-term Goals:
- Continued commercial development of new troponin assays.
Environmental Challenges
- Supply chain issues relating to plastics and chemical reagents.
- Turmoil in the energy market, predicting power outages.
- Limited candidate availability compromising progress in Board diversity.
Mitigation Strategies
- Expertly managed supply chain issues by procurement team.
- Planned to use diesel generator and reserve fuel supplies to minimize power outage disruption.
- Continued efforts to increase Board diversity.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Standards
Frameworks Used: Quoted Companies Alliance Corporate Governance Code
Certifications: ISO 9001:2015, ISO 13485:2016
Sustainable Products & Innovation
- Pyrene lateral flow system for industrial pollution biomonitoring
- Assays for benzene and isocyanates